logo
Share SHARE
FONT-SIZE Plus   Neg

Amgen's PCSK9 Inhibitor Lowers LDL Cholesterol Up To 81%

Amgen Inc. (AMGN) Sunday reported positive results from phase 1b study of AMG 145, an investigational PCSK9 inhibitor, in patients with high cholesterol who were taking statins. The study revealed that multiple doses of the drug significantly reduced LDL, or bad cholesterol, by up to 81 percent compared to placebo in patients on low to moderate doses of statins.

AMG 145 is a fully human monoclonal antibody that inhibits PCSK9, a protein that reduces the liver's ability to remove LDL-C from the blood. High LDL cholesterol is the main contributor to the risk of developing cardiovascular disease.

In the 51-patient study, the subjects who received AMG 145 every two weeks in combination with low to moderate doses of statins had LDL reductions of up to 75 percent versus placebo at sixth week.

Meanwhile, the subjects who received AMG 145 in combination of low to moderate doses of statins every four weeks showed up to a 66 percent reduction in LDL at eighth week.

Patients on high doses of statins who received AMG 145 every two weeks had a reduction in LDL of up to 63 percent versus placebo at sixth week, the company said.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Cisco Systems Inc. (CSCO), the world's largest computer networking gear maker, is accelerating its ability to deliver on growth opportunities, aggressively driving its cloud business, and delivering continued strength in its deferred product revenue, as we sell more of its portfolio in software and cloud models. In fiscal 2016, the company sees a 25% increase in major new product introductions. Sanofi (SNYNF, SNY) reported that its fourth-quarter net income attributable to equity holders decreased to 334 million euros from 1.34 billion euros, last year. Earnings per share was 0.26 euros compared to 1.02 euros. Earnings per share excluding the held for exchange Animal Health Business was 0.41... Tour operator TUI Group reported narrower EBITA loss in its first quarter with increased turnover, driven by strong performances in Northern Region and Cruises. Further, the company said its current trading for Winter 2015/2016 and Summer 2016 remains in line with its expectations. Looking ahead, TUI reiterated its outlook to deliver underlying EBITA growth of at least 10 percent in fiscal 2016.
comments powered by Disqus
RELATED NEWS
Trade AMGN now with 
Follow RTT